GORDON RESEARCH CONFERENCE ON CANCER, 1985
戈登癌症研究会议,1985 年
基本信息
- 批准号:3433860
- 负责人:
- 金额:$ 1.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-06-01 至 1986-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Funds were requested for travel, and room and board for speakers and
session moderators at the 39th Gordon Conference on Cancer, August 19-23,
1985, at Colby-Sawyer College in New London, New Hampshire.
The themes of the meeting were tumor heterogeneity and tumor progression,
and the genetic and epigenetic factors that play a role in the expression
of these phenomena. Related topics on differentiation, drug resistance and
therapy were included. The topics were deliberately diverse in order to
encourage the participation of cell biologists, pharmacologists, molecular
biologists, clinicians, pharmacologists, immunologists and pathologists.
The areas were diverse but interrelated, and provided a unifying theme
throughout the meeting.
The meeting format was designed to achieve these goals by maximizing
discussion. There were about 150 attendees drawn from academic, clinical,
industrial, and governmental laboratories. There were only three morning
and two evening speakers. Thirty minutes of discussion time followed each
thirty minutes of presentation. The discussion leaders were prepared to
offer constructive criticism, comparison with related work, and analysis of
implications. A poster session, on-campus housing and dining, and free
afternoons in a scenic but isolated setting fostered further exchange. (T)
请拨经费用于旅行,并为演讲者和
第39届戈登癌症会议的主持人,8月19-23日,
1985年,在新罕布夏州新伦敦的科尔比-索耶学院学习。
会议的主题是肿瘤异质性和肿瘤进展,
以及在表达中起作用的遗传和表观遗传因素
这些现象。有关分化、抗药性和
治疗包括在内。主题故意多样化,目的是为了
鼓励细胞生物学家、药理学家、分子科学家的参与
生物学家、临床医生、药理学家、免疫学家和病理学家。
这些领域是不同的,但又相互关联,提供了一个统一的主题
在整个会议期间。
会议形式旨在通过最大限度地
讨论。大约150名与会者来自学术界、临床界、
工业和政府实验室。只有三个上午
和两位晚间演讲者。每个人都有30分钟的讨论时间
30分钟的陈述。讨论的领导者们准备
提供建设性的批评,与相关工作进行比较,并对
这意味着什么。海报会议,校内住宿和餐饮,免费
在一个风景秀丽但与世隔绝的环境中的下午促进了进一步的交流。(T)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC J. STANBRIDGE其他文献
ERIC J. STANBRIDGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC J. STANBRIDGE', 18)}}的其他基金
Single Cell Analysis of Cross Talk Among Kinase Pathways
激酶通路间串扰的单细胞分析
- 批准号:
7178789 - 财政年份:2005
- 资助金额:
$ 1.15万 - 项目类别:
Single Cell Analysis of Cross Talk Among Kinase Pathways
激酶通路间串扰的单细胞分析
- 批准号:
7324436 - 财政年份:2005
- 资助金额:
$ 1.15万 - 项目类别:
Single Cell Analysis of Cross Talk Among Kinase Pathways
激酶通路间串扰的单细胞分析
- 批准号:
6872729 - 财政年份:2005
- 资助金额:
$ 1.15万 - 项目类别:
Single Cell Analysis of Cross Talk Among Kinase Pathways
激酶通路间串扰的单细胞分析
- 批准号:
7055189 - 财政年份:2005
- 资助金额:
$ 1.15万 - 项目类别:
Single Cell Analysis of Cross Talk Among Kinase Pathways
激酶通路间串扰的单细胞分析
- 批准号:
6999728 - 财政年份:2005
- 资助金额:
$ 1.15万 - 项目类别:
DOMINANT-NEGATIVE AND GAIN OF FUNCTION P53 MUTATIONS
P53 显性失活和功能获得突变
- 批准号:
6164194 - 财政年份:1996
- 资助金额:
$ 1.15万 - 项目类别:
DOMINANT-NEGATIVE AND GAIN OF FUNCTION P53 MUTATIONS
P53 显性失活和功能获得突变
- 批准号:
2882426 - 财政年份:1996
- 资助金额:
$ 1.15万 - 项目类别:
EVALUATION OF DOMINANTLY-ACTING RAS ONCOGENES
对起主导作用的 RAS 癌基因的评估
- 批准号:
2668028 - 财政年份:1996
- 资助金额:
$ 1.15万 - 项目类别:
DOMINANT-NEGATIVE AND GAIN OF FUNCTION P53 MUTATIONS
P53 显性失活和功能获得突变
- 批准号:
2376977 - 财政年份:1996
- 资助金额:
$ 1.15万 - 项目类别:
EVALUATION OF DOMINANTLY-ACTING RAS ONCOGENES
对起主导作用的 RAS 癌基因的评估
- 批准号:
2113574 - 财政年份:1996
- 资助金额:
$ 1.15万 - 项目类别:
相似海外基金
Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
- 批准号:
MR/Y002164/1 - 财政年份:2024
- 资助金额:
$ 1.15万 - 项目类别:
Research Grant
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
- 批准号:
10638634 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
光滑念珠菌抗真菌药物耐药性中蛋白激酶的功能和转录组分析
- 批准号:
10643423 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
基于肽酶刺激的新方法用于靶向耐药性乳腺癌
- 批准号:
10713648 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
- 批准号:
10750627 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Reversing Drug Resistance in Tumors with Clickable Antibody Pairs
利用可点击的抗体对逆转肿瘤的耐药性
- 批准号:
10566266 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Mathematical Modeling of Drug Resistance Evolution and The Optimal Treatment Strategy in EGFR Mutated Lung Cancer
EGFR突变肺癌耐药演化的数学模型及最佳治疗策略
- 批准号:
22KJ0768 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Elucidation of prion strain-specific effect of antiprion drugs and drug resistance mechanisms
阐明抗朊病毒药物的朊病毒株特异性作用和耐药机制
- 批准号:
23H02828 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Targeting RAGE in tumor and TME to oppose inflammation and drug resistance in obesity associated ER+ breast cancer
靶向肿瘤和 TME 中的 RAGE,对抗肥胖相关 ER 乳腺癌的炎症和耐药性
- 批准号:
10734834 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Targeting chromosomal insatiability for overcoming drug resistance
针对染色体不饱和性克服耐药性
- 批准号:
23K08200 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)